Metformin and Dementia Risk: What a 20-Year Follow-Up Actually Found
A twenty-year follow-up of one of the most important diabetes trials ever conducted has produced the strongest signal yet that a common, inexpensive medication may help protect the aging brain. I want to walk you through what the researchers actually found, what they did not find, and what it means for the way you guard your memory starting this week.
Every week in my practice I meet someone who is far more afraid of losing their mind than losing their life. That fear is understandable. Alzheimer’s disease and related dementias remain among the few conditions in modern medicine where we still have very little to offer once the process is well underway. So when a study suggests that a drug already sitting in millions of medicine cabinets might cut dementia risk, it deserves a careful look.
The headline making its way across social media says that metformin, a first-line drug for type 2 diabetes that costs pennies a day, may cut later dementia risk by about half. The underlying research is real, it comes from a respected team, and it is genuinely interesting. It is also more complicated than a headline can hold.
The Numbers At A Glance
Where These Numbers Come From
To understand this study, you have to understand the trial behind it. In the late 1990s, researchers launched the Diabetes Prevention Program, a landmark clinical trial that enrolled thousands of adults with prediabetes and randomly assigned them to one of three groups: an intensive lifestyle program built around weight loss and physical activity, metformin, or a placebo.
That original trial ran a little over three years and delivered a clear answer on its primary question. Lifestyle change beat metformin at preventing the progression from prediabetes to full type 2 diabetes, and both beat placebo. Those findings reshaped how we counsel patients with rising blood sugar, and they still hold up.
But the researchers did something unusual and valuable. They kept following the participants. The Diabetes Prevention Program Outcomes Study has now tracked this same group for more than two decades, adding cognitive testing along the way. Between 2009 and 2024, participants completed memory and thinking assessments, and between 2022 and 2024 a panel adjudicated who had developed mild cognitive impairment or dementia.
That is what makes this analysis worth attention. Most of what we know about metformin and the brain comes from observational data, meaning researchers look at people who happened to take the drug and compare them to people who did not. That approach is riddled with confounding, because the people who take a medication differ from the people who do not in a hundred ways you cannot fully measure. Here, the original assignment was randomized. That is a meaningfully stronger foundation.
The Finding That Made Headlines
Among the 1,483 participants with cognitive outcome data, those originally randomized to metformin had roughly 60 percent lower odds of dementia compared with placebo (odds ratio 0.40, 95 percent confidence interval 0.17 to 0.97) and about 62 percent lower odds compared with the intensive lifestyle group (odds ratio 0.38, 95 percent confidence interval 0.16 to 0.89). The metformin group also performed better on memory testing.
Dr. José Luchsinger at Columbia University, who led the work, has described this as the strongest evidence available short of a trial designed specifically around dementia. I think that is a fair characterization.
“When a randomized trial and decades of patience line up behind a finding, I pay attention. But paying attention and changing my prescribing are two very different things.”
Dr. Don Colbert, MD
Now, The Part Most Headlines Left Out
I have been practicing medicine long enough to have watched a great many promising findings evaporate under scrutiny. So let me lay out the honest limitations, because you deserve them.
Four things to hold in mind
1. This is a preprint. The analysis was posted to a preprint server, which means it has not yet completed peer review. Preprints are how modern science moves quickly, and they are useful. They are not final.
2. The estimates are imprecise. The authors say so plainly. There were relatively few dementia cases, and when case counts are small, the confidence intervals stretch wide. Notice that the upper bound of the comparison against placebo reaches 0.97, which sits right at the edge of statistical significance.
3. The overall picture was more muted. When researchers looked at the full distribution of cognitive syndromes across all three groups, the differences were not statistically significant. The dementia signal is a piece of the picture, not the whole of it.
4. This trial was never designed to study the brain. Cognition was added later. That is a legitimate way to generate a hypothesis. It is not the same as testing one.
There is also an oddity worth sitting with. The intensive lifestyle group, the arm that did the best job preventing diabetes itself, showed the highest dementia rate of the three. If the entire benefit were simply about better blood sugar control, you would expect the lifestyle group to do at least as well as metformin. It did not. Either something specific to the drug is at work, or the numbers are noisier than they appear. Both explanations are live.
Why Blood Sugar And The Brain Are So Tightly Linked
Whatever the final verdict on metformin, the broader connection here is not in dispute, and it is the part I want you to carry with you.
Researchers have started calling Alzheimer’s disease “type 3 diabetes,” and while that label is an oversimplification, it points at something real. The brain is a spectacularly energy-hungry organ. It makes up about two percent of your body weight and consumes roughly twenty percent of your energy. When insulin signaling breaks down in brain tissue, neurons struggle to access the fuel they need. Chronic high blood sugar also damages the small vessels that feed the brain, drives inflammation, and accelerates the formation of advanced glycation end products, which are exactly as unpleasant as they sound.
Worth Knowing
People with type 2 diabetes carry roughly a 50 to 70 percent higher risk of developing dementia than people without it. That relationship has been documented across many populations and many years, and it is far more established than any single drug finding.
The possible mechanisms proposed for metformin follow that same logic: reduced vascular inflammation, better glucose handling, and shifts in immune signaling. None has been proven to be the main pathway. The researchers are candid about that.
Should You Ask Your Doctor For Metformin?
Let me be direct, because I think vagueness does patients a disservice here.
No, not on the basis of this study. This finding does not license anyone to prescribe metformin as an anti-dementia pill, and any physician who tells you otherwise is getting ahead of the evidence. Metformin is a well-tolerated drug with a long safety record, but it is not free of consequence. It can cause significant gastrointestinal upset. It is associated with vitamin B12 depletion over the long term, which carries its own neurological implications, and I check B12 levels in every patient of mine who takes it for an extended period. It is not appropriate for people with certain kidney or liver conditions.
What this research does justify is the set of trials now underway testing metformin directly against Alzheimer’s disease and related decline, some in combination with lifestyle programs. If those confirm a benefit, we will have something remarkable: an inexpensive, widely available tool against a disease that is otherwise devastating to treat. That is a result worth waiting for properly.
If you already take metformin for diabetes or prediabetes, this is quiet encouragement to keep taking it as prescribed. If you do not, the conversation to have with your physician is about your metabolic health as a whole, not about one drug.
A Word Of Encouragement
“For God hath not given us the spirit of fear; but of power, and of love, and of a sound mind.”
2 TIMOTHY 1:7
I quote that verse often, and not casually. Fear of cognitive decline can itself become corrosive, driving people toward expensive supplements they do not need and away from the ordinary, unglamorous habits that carry the real evidence. A sound mind is worth stewarding well, and stewardship looks less like chasing headlines and more like faithfulness in small daily things.
What Actually Moves The Needle Right Now
Here is what frustrates me about the way these stories travel. The metformin finding is uncertain and years from being actionable. Meanwhile, the interventions with the strongest evidence for protecting cognition are available to you this afternoon and cost nothing.
The Lancet Commission on dementia prevention has estimated that a substantial share of dementia cases worldwide are linked to modifiable risk factors. Not all of them, and not with certainty for any individual person. But a meaningful share. That is where your energy belongs.
Seven Steps I Give My Own Patients
The Bottom Line
A twenty-year randomized follow-up found that people originally assigned to metformin had substantially lower odds of developing dementia. The finding is real, it is the strongest of its kind so far, and it is also preliminary, imprecise, not yet peer reviewed, and drawn from a trial that was never built to answer this question.
Hold it loosely. Watch for the dedicated trials. And in the meantime, put your effort where the evidence is already settled: stabilize your blood sugar, move your body, sleep well, protect your hearing, and stay connected to the people God has placed around you. Those are not consolation prizes while we wait for a drug. They are the main event.
Frequently Asked Questions
Does metformin prevent Alzheimer’s disease?
No study has shown that. This research found lower odds of dementia among people randomized to metformin decades earlier, but the estimates were imprecise, the analysis has not been peer reviewed, and dedicated trials testing metformin against Alzheimer’s are still in progress.
Can I take metformin if I do not have diabetes?
Metformin is a prescription medication and its off-label use for longevity or brain health remains unproven and is an individual decision to make with your physician. It carries real side effects, including gastrointestinal symptoms and long-term vitamin B12 depletion.
Why did the lifestyle group have more dementia than the metformin group?
That is one of the puzzling aspects of the results and the researchers do not have a confirmed explanation. It may reflect a drug-specific mechanism, or it may reflect statistical noise from a small number of dementia cases. This is precisely why the findings need confirmation.
Is high blood sugar really connected to dementia risk?
Yes, and this part is well established independent of any metformin finding. Type 2 diabetes is associated with a substantially elevated risk of dementia, likely through vascular damage, chronic inflammation, and impaired insulin signaling in brain tissue.
Sources
Luchsinger, J. A., et al. (2026). Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes Study. medRxiv preprint. DOI: 10.64898/2026.08.05.26359234.
Diabetes Prevention Program Research Group. Long-term follow-up analyses, Diabetes Care, 2025.
Livingston, G., et al. Dementia prevention, intervention, and care: Lancet Commission reports.
Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Metformin is a prescription medication and should only be taken under the supervision of a licensed healthcare provider. Always consult your physician before starting, stopping, or changing any medication or supplement, particularly if you are pregnant, nursing, managing a medical condition, or taking other medications.
